WHO Sounds Concern Over Critical Lack of Obesity Medications
Under one in 10 people eligible to benefit from weight-loss injections such as Wegovy can access them, caution the World Health Organization as it releases its initial recommendations on the medications.
With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for increased and just availability to these injectable treatments.
Per projections, over two billion could be living with obesity by 2030 unless action is taken.
"The latest guidelines recognises that excess weight is a lifelong illness that can be addressed with comprehensive and ongoing care," stated its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are significant hurdles to widespread availability to the treatments that can assist patients in reducing considerable weight, explains the agency.
GLP-1 Therapy Shortage
Despite the current most favorable case, the production of such drugs could only cover around 100 million people – fewer than 10% of those who need them, per the health organization.
The advice calls on nations and manufacturers to widen availability, via measures including licensing agreements.
Exclusive production rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple nations in 2026.
The Way Weight-Loss Injections Function
These medications mimick a biological compound to reduce digestion speed, suppress the appetite and boost the sense of being full so people eat less.
Individuals usually start to lose weight after several weeks of commencing the once-weekly jabs.
Studies suggests people may see weight return within a year of discontinuing the treatment, as their normal food cravings come back.
To be above a healthy weight increases your chance for developing health problems, like diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight affects people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the health agency.
